科伦博泰生物(06990.HK)治疗肺癌药物获国家药监局批准第二个适应症

阿斯达克财经
Mar 10

科伦博泰生物-B(06990.HK) 公布,旗下靶向人滋养细胞表面抗原2(TROP2)的抗体药物偶联物(ADC)芦康沙妥珠单抗,获国家药品监督管理局(NMPA)批准第二个适应症,用于治疗经表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI),和含铂化疗治疗后进展的EGFR基因突变阳性的局部晚期,或转移性非鳞状非小细胞肺癌(NSCLC)成人患者。

公告指,科伦博泰生物于2022年5月授予默沙东,在大中华区(包括中国内地、香港、澳门及台湾)以外的所有地区开发、使用、制造及商业化芦康沙妥珠单抗的独家权利。(js/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-10 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10